Home › Funds › BENDER ROBERT & ASSOCIATES › ABT

BENDER ROBERT & ASSOCIATES position in ABT

ABBOTT LABORATORIES · Health Care

BENDER ROBERT & ASSOCIATES reported holding 2,905 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$287K, representing 0.05% of its reported portfolio and ranking #39 among its reported holdings. BENDER ROBERT & ASSOCIATES has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.90K sh
Reported value held$287.10K
Portfolio Weight0.05%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How BENDER ROBERT & ASSOCIATES's ABT position evolved

BENDER ROBERT & ASSOCIATES first disclosed a stake in ABT in Q3 2023 at 7,316 shares (US$709K). The position peaked in Q4 2023 at 7,134 shares, worth US$785K. Across 13 filings, BENDER ROBERT & ASSOCIATES increased the stake 1 time(s), trimmed it 9 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,905 shares valued at US$287K. Notable position changes include a 28% trim in Q1 2025 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 7.32K $708.55K New
Q4 2023 7.13K $785.24K Reduce
Q1 2024 6.82K $774.82K Reduce
Q2 2024 5.81K $603.82K Reduce
Q3 2024 5.77K $657.95K Reduce
Q4 2024 5.64K $637.71K Reduce
Q1 2025 4.08K $541.88K Reduce
Q2 2025 4.12K $559.62K Add
Q3 2025 4.07K $544.40K Reduce
Q4 2025 3.10K $389.02K Reduce
Q1 2026 2.90K $298.26K Reduce
Q2 2026 2.90K $263.60K Hold
Q3 2026 2.90K $287.10K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has BENDER ROBERT & ASSOCIATES held ABT?

BENDER ROBERT & ASSOCIATES has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is BENDER ROBERT & ASSOCIATES's current position in ABT?

As of Q3 2026, BENDER ROBERT & ASSOCIATES holds 2.90K shares of ABT (ABBOTT LABORATORIES), valued at $287.10K, representing 0.05% of its reported portfolio and ranking #39.

Has BENDER ROBERT & ASSOCIATES been buying or selling ABT?

In the latest 13F filing (Q3 2026), BENDER ROBERT & ASSOCIATES held unchanged its position in ABT. The position peaked in Q4 2023 at 7.13K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.